Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Datopotamab deruxtecan + MEDI5752 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Datopotamab deruxtecan | Datroway | Dato-DXd|DS1062a|DS 1062a|DS-1062a|datopotamab deruxtecan-dlnk | TROP2 Antibody 19 | Datroway (datopotamab deruxtecan) is an antibody-drug conjugate (ADC) comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). Datroway (datopotamab deruxtecan) is FDA-approved for use in patients with unresectable or metastatic, hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received prior endocrine-based therapy and chemotherapy, and in patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy (FDA.gov). |
| MEDI5752 | MEDI-5752|MEDI 5752|volrustomig | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 137 | MEDI5752 is a bispecific human IgG1 monoclonal antibody that binds PD1 (PDCD1) and CTLA4, potentially resulting in enhanced anti-tumor immune response (Cancer Res 2018;78(13 Suppl):Abstract nr 2776). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|